Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Recruiting · NCT05783323 · Registry updated 2025-11-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Site, cancer, childhood malignant neoplasm, differentiated thyroid carcinoma, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor | Recruiting | Phase 2 | 2025-11-14 | NCT05783323 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bayer | 178 |
| Children's Hospital of Philadelphia | 215 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Seattle Children's Hospital | Seattle | United States | 281 |
| St. Jude Children's Research Hospital | Memphis | United States | 1 |
| University of California, San Francisco | San Francisco | United States | 14 |